Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-CD19 CAR-T cells |
Synonyms | |
Therapy Description |
Anti-CD19 CAR-T cells are T-cells that express a chimeric antigen receptor that targets the CD19 surface protein on B-lymphocytes, which results in anti-tumor activity in B-cell malignancies (PMID: 25999455, PMID: 26425336). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-CD19 CAR-T cells | CD19 Immune Cell Therapy 62 | Anti-CD19 CAR-T cells are T-cells that express a chimeric antigen receptor that targets the CD19 surface protein on B-lymphocytes, which results in anti-tumor activity in B-cell malignancies (PMID: 25999455, PMID: 26425336). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G12D | B-lymphoblastic leukemia/lymphoma | predicted - sensitive | Anti-CD19 CAR-T cells | Case Reports/Case Series | Actionable | In a clinical case study, treatment with an investigational anti-CD19 CAR-T cells therapy resulted in rapid elimination of leukemic cells, including a subclone harboring NRAS G12D, in a patient with relapsed Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia, the NRAS G12D subclone remained undetectable at disease progression 6 weeks after treatment (PMID: 31905241). | 31905241 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT01087294 | Phase I | Anti-CD19 CAR-T cells | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT06227026 | Phase I | Anti-CD19 CAR-T cells | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) | Recruiting | USA | 0 |
NCT05779930 | Phase I | Anti-CD19 CAR-T cells | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | Not yet recruiting | USA | 0 |
NCT03016377 | Phase Ib/II | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | Recruiting | USA | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT03938987 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) | Recruiting | CAN | 0 |
NCT05707273 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | Recruiting | USA | 0 |